A hexon-specific PEGylated adenovirus vector utilizing blood coagulation factor X

Area of Science:

• Biotechnology
• Gene Therapy
• Virology

Background:

• Previous hexon-specific PEGylated adenovirus (Ad) vectors aggregated due to avidin-biotin interactions, reducing in vivo transduction efficiency.
• Systemic administration of aggregated Ad vectors led to poor organ targeting and reduced therapeutic efficacy.

Purpose of the Study:

• To develop a novel method for hexon-specific PEGylation of Ad vectors using blood coagulation factor X (FX).
• To evaluate the in vivo performance of PEGylated Ad vectors (PEG-FX-Ad) in terms of blood retention and organ transduction.

Main Methods:

• Adenovirus vectors were mixed with PEGylated blood coagulation factor X (PEG-FX) to create PEG-FX-Ad vectors.
• PEG-FX-Ad vectors were administered intravenously into conventional and warfarinized mice.
• Blood retention and liver transduction efficiencies were assessed in both groups of mice.
• In vitro studies investigated the dissociation of PEG-FX from Ad vectors upon incubation with unmodified FX.

Main Results:

• PEG-FX-Ad vectors exhibited prolonged blood retention in conventional mice.
• Liver transduction efficiencies were not significantly reduced by PEG-FX in conventional mice.
• Warfarinized mice showed a significant reduction in liver transduction with PEG-FX-Ad vectors.
• Dissociation of PEG-FX from Ad vectors was observed in vitro, suggesting substitution by endogenous FX in vivo.

Conclusions:

• Blood coagulation factor X (FX) can serve as an adaptor molecule for hexon-specific modification of Ad vectors.
• PEG-FX-Ad vectors demonstrate potential for improved gene therapy delivery by enhancing circulation time.
• The substitution of PEG-FX by endogenous FX in vivo warrants further investigation for optimizing therapeutic strategies.